A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities

Conditions:   Cognitive Dysfunction;   Alzheimer's Disease Interventions:   Drug: Aducanumab;   Drug: Placebo Sponsor:   Biogen Not yet recruiting

Source: ClinicalTrials.gov - August 21, 2018 Category: Research Source Type: clinical trials